NEURO-HUMORAL MEDIATORS IN PROGRESSION OF ISCHEMIC HEART DISEASE WITH CONCOMITANT OBESITY
PDF

Keywords

acute myocardial infarction, iscemic heart disease, obesity, copeptin, MRproADM

Abstract

NEURO-HUMORAL MEDIATORS IN PROGRESSION OF ISCHEMIC HEART DISEASE WITH CONCOMITANT OBESITY.

Ryndina N., Kravchun P., Yermak A.

Cardiovascular disease is the main cause of death worldwide. Priority in the structure of the cardiovascular disease belongs to coronary artery disease (CAD) and especially to its acute form - acute myocardial infarction. AMI largely determines mortality, economic losses in most countries of the world. Modern epidemiological studies have shown the relationship between obesity and cardiovascular diseases, as well as between obesity and individual cardiovascular risk factors such as hypertension and hyperlipidemia. Cardiac troponin is a biomarker of choice for the diagnosis of acute myocardial infarction. However, after reperfusion therapy the actual level of Tn may be misleading due to the phenomenon of washout and the 12-hour expectation of peak levels remains the Achilles heel of this biomarker.Activation of neurohumoral systems in the acute period of the myocardial infarction promotes the expansion of the necrosis zone, the development of myocardial ischemia, abnormal heart rhythm and acute heart failure. Despite the large number of detected and studied neurohormones, our knowledge of the role of these peptides in the development of myocardial infarction and its complications is very limited. That is why studying of new biomarkers, such as copeptin and midregional proadrenomedullin, is perspective and interesting for scientist all over the world.

Keywords: acute myocardial infarction, iscemic heart disease, obesity, copeptin, MRproADM.

 

Абстракт

НЕЙРО-ГУМОРАЛЬНІ МЕДІАТОРИ ПРИ ПРОГРЕСУВАННІ ІШЕМІЧНОЇ ХВОРОБИ СЕРЦЯ З СУПУТНІМ ОЖИРІННЯМ.

Риндіна Н., Кравчун П., Єрмак О.

Серцево-судинні захворювання є основною причиною смерті в усьому світі. Пріоритет в структурі серцево-судинних захворювань належить ішемічній хворобі серця і особливо гострому інфаркту міокарда. Гострий інфаркт міокарда в чому визначає смертність, економічні втрати в більшості країн світу. Сучасні епідеміологічні дослідження показали зв'язок між ожирінням і серцево-судинними захворюваннями, а також між ожирінням і окремими факторами ризику серцево-судинних захворювань, такими як артеріальна гіпертензія і гіперліпідемія. Тропонін є маркером вибору для діагностики інфаркту міокарда. Однак після реперфузійної терапії фактичний рівень тропоніну може вводити в оману через явища вимивання, а 12-годинне очікування пікових рівнів залишається ахіллесовою п'ятою цього біомаркеру. Активація нейрогуморальних систем в гострому періоді інфаркту міокарда сприяє розширенню зони некрозу, розвитку ішемії міокарда, порушень ритму серця і гострої серцевої недостатності. Незважаючи на велику кількість виявлених і вивчених нейрогормонів, наші знання про роль цих пептидів у розвитку інфаркту міокарда та його ускладнень дуже обмежені. Ось чому вивчення нових біомаркерів, таких як копептин і MRproADM, є перспективним і цікавим для науковців усього світу.

Ключові слова: гострий інфаркт міокарда, ішемічна хвороба серця, ожиріння, копептин, MRproADM.

 

Абстракт

НЕЙРО-ГУМОРАЛЬНЫЕ МЕДИАТОРЫ ПРИ ПРОГРЕССИРОВАНИИ ИШЕМИЧЕСКОЙ БОЛЕЗНИ СЕРДЦА С СОПУТСТВУЮЩИМ ОЖИРЕНИЕМ.

Рындина Н., Кравчун П. Ермак А.

Сердечно-сосудистые заболевания являются основной причиной смерти во всем мире. Приоритет в структуре сердечно-сосудистых заболеваний принадлежит ишемической болезни сердца и особенно острому инфаркту миокарда. Острый инфаркт миокарда во многом определяет смертность, экономические потери в большинстве стран мира. Современные эпидемиологические исследования показали связь между ожирением и сердечно-сосудистыми заболеваниями, а также между ожирением и отдельными факторами риска сердечно-сосудистых заболеваний, такими как артеральная гипертензия и гиперлипидемия. Тропонин является маркером выбора для диагностики инфаркта миокарда. Однако после реперфузионной терапии фактический уровень тропонина может вводить в заблуждение из-за явления вымывания, а 12-часовое ожидание пиковых уровней остается ахиллесовой пятой этого биомаркера. Активация нейрогуморальных систем в остром периоде инфаркта миокарда способствует расширению зоны некроза, развитию ишемии миокарда, нарушений ритма сердца и острой сердечной недостаточности. Несмотря на большое количество обнаруженных и изученных нейрогормонов, наши знания о роли этих пептидов в развитии инфаркта миокарда и его осложнений очень ограничены. Вот почему изучение новых биомаркеров, таких как копептин и MRproADM, является перспективным и интересным для ученых всего мира.

Ключевые слова: острый инфаркт миокарда, ишемическая болезнь сердца, ожирение, копептин, MRproADM.

https://doi.org/10.35339/ic.6.4.200-209
PDF

References

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet / R. Lozano, M. Naghavi, K. Foreman [et al.] // 2012. – 380. – Р. 2095–2128.

The contribution of risk factor trends to cardiometabolic mortality decline in industrialized countries /M. Di Cesare, J. E. Bennette, N. Best [et al.] // Int J Epidemiol. – 2013. – N 42. – Р. 838–848.

Coronary heart disease epidemics: Not all the same / M. Mirzaei, A. S. Truswell, R. Taylor [et al.] // Heart. – 2009. – 95. – Р. 740–746.

Assessing the global burden of ischemic heart disease. Part 1: Methods for a systematic review of the global epidemiology of ischemic heart disease in 1990 and 2010 /A. E. Moran, J. T. Oliver, M. Mirzaie [et al.] // Global Heart. – 2012. –Vol. 7, N 4 – Р. 315–329.

Aspiration Thrombectomy During Primary Percutaneous Coronary Intervention as Adjunctive Therapy to Early (in-ambulance) Abciximab Administration in Patients with Acute ST Elevation Myocardial Infarction: An Analysis from Leiden MISSION! Acute Myocardial Infarction Treatment Optimization Program / T. Ahmed, J. Atary, R. Wolterbeek [et al.] // Journal of Interventional Cardiology. – 2012. – Vol. 25, N 1. – P. 1–9.

MGuard Mesh-Covered Stent for Treatment of ST-Segment Elevation Myocardial Infarction with High Thrombus Burden Despite Manual Aspiration / R. Romaguera, J. A. Gomez, G. R. Romaguera [et al.] // Journal of Interventional Cardiology. – 2013. – Vol. 26. – N 1. – P. 1–7.

Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project / R. M. Conroy, K. Pyorala, A. P. Fitzgerald [et al.] // Eur. Heart J. – 2003. – N 24. – P. 987–1003.

Salto-Tellez M. Myocardial infarction in the C57BL/6J mouse: A quantifiable and highly reproducible experimental model / M. Salto-Tellez, S. Lim, R. Menshawe // Cardiovascular Pathology. – 2004. – Vol. 13. –N 2. – P. 91–97.

Borne S. Increased matrix metalloproteinase-8 and -9 activity in patients with infarct rupture after myocardial infarction / S. Borne, J. Cleut-jens, R. Hanemaaijer // Cardiovascular Pathology. – 2009. – Vol. 18. – N 1. – P. 37–43.

Zhang Y. Timing of bone marrow cell therapy is more important than repeated injections after myocardial infarction / Y. Zhang, R. Sievers, M. Prasad // Cardiovascular Pathology. – 2011. – Vol. 20. – № 4. – P. 204–212.

Impaired renal function in patients with myocardial infarction treated with primary angioplasty and the risk for failed myocardial tissue reperfusion and thus worse long-term outcomes / D. Karwowski, Ł. Kalińczuk, K. Majewski [et al] // Postep Kardiol Inter. – 2012. – Vol. 8. – № 27. – P. 18–24.

An adaption of the Framingham coronary heart disease risk function to European Mediterranean areas / J. Marrugat, R. D'Ago-stino, L. Sullivan [et al.] // J. Epidemiol. Comm. Health. – 2003. – № 53. – P. 634–638.

Red versus white thrombi in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: clinical and angiographic outcomes / A. S. Quadros, E. Cambruzzi, J. Sebben [et al.] // American Heart Journal. – 2012. – Vol. 164. – N 4. – P. 553–560.

Cannabis joint triggered recurrent anterior myocardial infarction in an adolescent taking dual anti-platelet therapy / I. Biyik, I. F. Akturk, A. A. Yalcin [et al.] // Postep Kardiol Inter. – 2012. – Vol. 8. – N 28. – P. 156–159.

Trends in case-fatality in 117,718 patients admitted with acute myocardial infarction in Scotland / S. Capewell, M. Livingston, K. Maclntyre [et al.] //Eur. Heart J. – 2000. – N 21. – P. 1833–1840.

Altered melusin pathways involved in cardiac remodeling following acute myocardial infarction / R. Gu, D. Zheng, J. Bai [et al.] // Cardiovascular Pathology. – 2012. – Vol. 21. – N 2. – P. 105–111.

Siudak Z. ST-elevation myocardial infarction with local infu-sion of abciximab using thrombectomy catheter in a patient with very late stent thrombosis / Z. Siudak, J. Godlewski, L. Badacz // Postep Kardiol Inter. – 2012. – Vol. 8. – N 30. – P. 338–341.

A Comparison of Intracoronary with Intravenous Glyco-protein IIb/IIIa Inhibitors During Percutaneous Coronary Intervention in 157 Patients with Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials / G. Fu, L. Jia, Y. Wang [et al.] //Journal of Interventional Cardiology. – 2012. – Vol. 25, N 3. – P. 223–234.

Assiri A. Chronic lymphocytic leukemia involving the coronary arteries with accompanying acute myocardial infarction / A. Assiri, M. Lamba, J. Veinot // Cardiovascular Pathology. – 2005. – Vol. 14. – N 6. –P. 324–326.

Lack of association between factor V Leiden and pro-thrombin G20210A polymorphisms in Tunisian subjects with a history of myocardial infarction / D. Slama, N. Fekih-Mrissa, A. Haggui [et al.] // Cardiovascular Pathology. – 2013. – Vol. 22. – N 1. – P. 39–41.

Rationale and Design of the On-Treatment PLAtelet Reactivity-Guided Therapy Modification FOR ST-Segment Elevation Myocardial Infarction (PLATFORM) Randomized Trial / I. Mrdovic, L. Savic, G. Krljanac [et al.] // Journal of Interventional Cardiology. – 2013. – Vol. 26. – N 3. – P. 221–227.

Impact of age on treatment and outcomes in ST-elevation myocardial infarction / M. C. Newell, J. T. Henry, T. D. Henry [et al.] // American Heart Journal. – 2011. – Vol. 161. – N 4. – P. 664–672.

Bosetti C. Smoking and acute myocardial infarction among women and men: a case-control study in Italy / C. Bosetti, E. Negri, A. Tavani // Prev. Med. – 1999. – Vol. 29. – № 5. – P. 343–348.

Heidland U. E. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. / U. E. Heidland, B. E. Strauer // Circulation. – 2001. – Vol. 104. – P. 1477–1482.

DeFronzo R. A. Insulin resistance, hyperinsulinemia, and coronary artery disease: A complex metabolic web / R. A. DeFronzo // J Cardiovasc. Pharmacol. – 1992. – Vol. 20, N 11. – P. 1–16.

Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group II: Pathogenesis of Atherosclerosis in Diabetes / R.H. Eckel, M. Wassef, A. Chait [et al.]// Circulation.– 2002.– Vol. 105, N 18. – P. 138–143.

Eskel R. H. American Heart Association call to action: obesity as a major risk factor for coronary heart disease / R. H. Eskel, R. M. Krauss // Circulation. – 1998. – N 7. – Р. 2099–2100.

Grassi G. Role of sympathetic nervous system in human hypertension / G. J. Grassi // Hypertens. – 1998. – N 16. – Р. 1979–1987.

Prospective analyses of the insulin resistance syndrome (Syndrome X) / S. M. Haffner, R. A. Valdez, H. P. Hazuda [et al.] // Diabetes. – 1992. – Vol. 41, N 6. – P. 715–722.

Alpert M. A. Obesity cardiomyopathy; pathophysiology and evolution of the clinical syndrome / M. A. Alpert // Am J Med Sci. – 2001. – Vol. 321, N 4. – Р. 225–236.

Hypertension and obesity / A. Aneja, F. El-Atat, S. I. McFarlane [et al.] // Recent Progr Horm Res. – 2004. – Vol. 59. – Р. 169–205.

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study / S. Yusuf, S. Hawken, S. Ounpuu [et al.]// Lancet. – 2004. – Vol. 364, N 9. – P. 937–952.

A prospective study of abdominal obesity and coronary artery calcium progression in older adults / C. K. Kramer, D. von Muhlen, L. Jorge [et al.] // JCEM. – 2009. – Vol. 94. – P. 5039–5044.

The predictive value of different measures of obesity for incident cardiovascular events and mortality / J. Harald, Schneider, N. Friedrich [et al.] // JCEM. – 2010. – N 95. – P. 1777–1785.

Adipocyte fatty acid-binding protein suppresses cardiomyocyte contraction. A new link between obesity and heart disease / V. Lamounier-Zepter, C. Look, J. Alvarez [et al.] // Circulation Research. – 2010. – Vol. 105. – N 4. – P. 326–334.

Van Itallie T. B. Health imnplications of overweight and obesity in the United States / T.B. Van Itallie // Ann. Intern. Med. – 1985. – Vol. 103. – P. 983–988.

Bays H. E. Adiposopathyis “sickfat” a cardiovascular disease? / H. E. Bays// J. Am. Coll. Cardiol. – 2011. – Vol. 57, N 25. – P. 2461 – 73.

ESC Guidelines for the management of acute myocardial infarction in

patients presenting with ST-segment elevation / Ph. G. Steg, S. K. James, D. Atar [et al.] // European Heart Journal. – 2012. – Vol. 33, N 20. – P. 2569–2619.

ESC Guidelines for the management of acute myocardial infarction in

patients presenting without persistant ST-segment elevation / M. Roffi, C. Patrono, J.-P. Collet [et al.] // European Heart Journal. – 2016. – Vol. 37, N 36. – P. 2737-2738.

Apple F.S. Analytical characteristics of high-sensitivity cardiac troponin assays / F. S. Apple, P. O. Collinson // Clinical Chemistry. – 2012. – Vol. 58, N 1. – P. 54–61.

Early dynamic change in high-sensitivity cardiac troponin T in the investigation of acute myocardial infarction / S. J. Aldous, A. M. Richards, L. Cullen [ et al.] // Clinical Chemistry. – 2011. – Vol. 57, N 8. – P. 1154–1160.

Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes / E. M. Antman, M. J. Tanasijevic, B. Thompson [et al.] // American College of Cardiology Committee for the redefinition of myocardial infarction. – 2000. – Vol. 36. – Р. 959–969.

Calcification after myocardial infarction is independent of amniotic fluid stem cell injection / D. Delo, X. Guan, Z. Wang [et al.] // Cardiovascular Pathology. – 2011. – Vol. 20. – № 2. – P. 69–78.

Sensitive troponin I assay in early diagnosis of acute myocardial infarction / T. Keller, T. Zeller, D. Peetz [et al.] // N Engl J Med. – 2009. – Vol. 361, N 9 –Р. 868–877.

Justin H. and Douglas L. Mann Neurohormonal activation in heart failure with reduced ejection fraction / H. Justin, L. Douglas // Nat Rev Cardiol. 2017 Jan; 14(1): 30–38.

Holwerda D. A. A glycopeptide from the posterior lobe of pig pituitaries. Isolation and characterization / D. A. Holwerda //. Eur J Biochem. – 2005. – Vol. 28, N 3. – Р. 334–339.

Morgenthaler N. G. Copeptin: a biomarker of cardiovascular and renal function / N. G. Morgenthaler // Congest Heart Fail. – 2010. – Vol. 16, N 1. – Р. 37–44.

Incremental value of copeptin for rapid rule out of acute myocardial infarction / T. Reichlin, W. Hochholzer, C. Stelzig [et al.] // J Am Coll Cardiol. – 2009. – Vol. 54, N 1. – P. 60–68.

Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level / M. Katan, .N Morgenthaler, I .Widmer [et al.] // Neuro Endocrinol Lett. – 2008. – Vol. 29. – P. 341–346.

Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators: Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial / M. Gheorghiade, W. A. Gattis, C. M. O'Connor [et al.] // JAMA. – 2004. – Vol. 291, N 16. – Р. 1963–1971.

Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level / M. Katan, .N Morgenthaler, I .Widmer [et al.] // Neuro Endocrinol Lett. – 2008. – Vol. 29. – P. 341–346.

Incremental value of copeptin for rapid rule out of acute myocardial infarction / T. Reichlin, W. Hochholzer, C. Stelzig [et al.] // J Am Coll Cardiol. – 2009. – Vol. 54, N 1. – P. 60–68.

C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study / S. Q. Khan , O. S. Dhillon, R. J. O’Brien [et al.] // Circulation. – 2007. – Vol. 115. – Р. 2103–2109.

Endogenous stress response in Takotsubo cardiomyopathy and acute myocardialinfarction/ J. Meissner, H. Nef, J .Darga [et al.] // Eur J Clin Invest. – 2011. – Vol. 41, N 9. – P. 964–970.

Combined testing of high-sensitivity troponin T and copeptin on presentation at prespecified cutoffsimproves rapid rule-out of non–ST-segment elevation myocardial infarction / E. Giannitsis, T. Kehayova, M. Vafaie [et al.] // Clin Chem. – 2011. – Vol. 57. – P. 1452–1455.

Copeptin improvesearly diagnosis of acute myocardial infarction / T. Keller, S. Tzikas, T. Zeller [et al.] // J. Am Coll Cardiol.– 2010. – Vol. 55. – P. 2096–2106.

Diagnostic accuracy of combined cardiac troponin and copeptin assessment for early rule-out of myocardial infarction: a systematic review and meta-analysis / T. Raskovalova, R. Twerenbold, P. O. Collinson [et al] // European Heart Journal: Acute Cardiovascular Care.– 2014.– Vol. 3, N 1.– P. 18–27.

Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective malmo diet and cancer study cardiovascular cohort / S. Enhörning, L. Bankin, N. Bouby [et al.] // Int J Obes (Lond) . – 2013. – Vol. 37. – P. 598–603.

Production and secretion of adrenomedullin from glial cell tumors and its effects on cAMP production / K. Takahashi, F. Satoh, E. Hara [et al.] // Peptides. –1997. – Vol. 18. – P. 1117–1124.

Jougasaki M. Adrenomedullin: potential in physiology and pathophysiology / M. Jougasaki, J.C. Burnett Jr // Life Sci. – 2000. – Vol. 66. – P. 855–872.

Adrenomedullin Inhibits Adipogenesis Under Transcriptional Control of Insulin / R. Harmancey, J.-. Senard, P. Roue[et al.] // Diabetes. – 2007. – Vol. 56. – Р. 553–563.

Potent and long-lasting vasodilatory effects of adrenomedullin in humans. Comparisons between normal subjects and patients with chronic heart failure / M. Nakamura, H. Yoshida, S. Makita [et al.] //Circulation. – 1997. – Vol. 95. – P. 1214 –1221.

Vari R. C. Renal effects of adrenomedullin in the rat / R. C. Vari, S. D. Adkins, W. K. Samson // Proc Soc Exp Biol Med. – 1996. – Vol. 211. – P. 178–183.

Hinson J. P. Adrenomedullin a multifunctionalregulatory peptide / J. P. Hinson, S. Kapas, D. M. Smith // Endocr Rev. – 2000. – Vol. 21, N 2. – P. 138–167.

Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma / N. G. Morgenthaler, J. Struck, B. Thomas [et al] // Clin Chem. – 2004. – Vol. 50. – P. 234–236.

Homogeneous time-resolved fluoroimmunoassay for the measurement of midregional proadrenomedullin in plasma on the fully automated system BRAHMS KRYPTOR® / P. Caruhel, C. Mazier, J. Kunde [et al] // Clin Biochem. – 2009. – Vol. 42, N 7-8. – P. 725–728.

Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in ACute Heart failure) trial / A. Maisel, C. Mueller, R. Nowak [et al.] // J Am Coll Cardiol. – 2010. – Vol. 55. –P. 2062–2076.

Short-term mortality risk in emergency department acute heart failure / W. F. Peacock, R. Nowak, R. Christenson [et al.] // Acad Emerg Med. – 2011. – Vol. 18, N 9. – P. 947–958.

ADHERE Investigators. Cardiac troponin and outcome in acute heart failure / W. F. 4th Peacock, T. De Marco, G. C. Fonarow [et al.] // N Engl J Med. – 2008. – Vol. 358, N 20. – P. 2117–2126.

The first clinical pilot study of intravenous adrenomedullin administration in patients with acute myocardial infarction / Y. Kataoka, S. Miyazaki, S. Yasuda [et al.] // J Cardiovasc Pharmacol. – 2010. – Vol. 56, N 4. – P. 413–419.

Assessment of myocardial injury by serum tumour necrosis factor alpha measurements in acute myocardial infarction / M. M. Hirschl, M. Gwechenberger, T. Binder [et al.] // Eur. Heart J. – 1996. – Vol. 17. – P. 1852–1859.

Copyright for articles published in the journal is regulated by the License Agreement for the use of a scientific article in the journal, which is concluded between the author of the article (Licensor) and Kharkov National Medical University (Licensee, publisher of the journal "Inter Collegas"). The licensor grants to the Licensee a non-exclusive non-exclusive license for the use of the article (a license that does not exclude the use of the article by the Licensor and the issuance of licenses to others for use of this article) on the terms and for the period specified in the contract. The licensor (the author of the article) grants the Licensee the right to reproduce the article (publication in the journal "Inter Collegas", publication, duplication, duplication or other reproduction of the article without limiting the circulation of copies, each copy of the article must contain the name of the Licensor; Of general information, including the publication of the article in full or in part on the Internet on the journal page, the right to use the metadata of the article (titles, full names of authors, annotations, bibliography eskih materials) through the dissemination and communication to the public, processing and systematization, as well as inclusion in various databases and in-formational system).

The licensor grants the licensee the right to transfer, store and process his personal data (full name, scientific degree, academic title, place of work and position, contact information of the authors) with the purpose of including them in the database in accordance with the Law of Ukraine No. 2297 - VI "on protection of personal data" from 01.06.2010.

Personal data and metadata of the article are provided for their storage and processing in various databases and information systems, including them in analytical and statistical reporting, creating sound relationships between the objects of works of science, literature and art with personal data, etc. on unlimited territory. The licensee has the right to transfer the specified data for processing and storage to third parties provided that such a fact is notified with the provision of information about the third party (name and address) to the Licensor.